RT Journal Article
SR Electronic
T1 Methotrexate in Psoriasis and Psoriatic Arthritis
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 31
OP 35
DO 10.3899/jrheum.200124
VO 96
A1 Laura C. Coates
A1 Joseph F. Merola
A1 Suzanne M. Grieb
A1 Philip J. Mease
A1 Kristina Callis Duffin
YR 2020
UL http://www.jrheum.org/content/96/31.abstract
AB Methotrexate (MTX) is the most commonly prescribed first-line therapy in psoriatic arthritis (PsA) internationally and is also commonly used in the treatment of psoriasis. However, data supporting its use in PsA are limited and significant toxicities can occur. This article summarizes a debate at the 2019 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) annual meeting that focused on the use of MTX in psoriasis and PsA. Four clinicians and 1 patient research partner presented clinical study data and the patient experience summarizing the efficacy, tolerability, and toxicity of MTX for both skin and musculoskeletal manifestations. A survey of attending GRAPPA members collected data on current and planned future use of MTX across the world.